Based on preliminary figures for the Third Quarter 2017, Hofseth BioCare ASA
(HBC) management expects to report group revenues of approximately NOK 28m for
the quarter, compared to NOK 3.6m in the same quarter 2016.
The cash balance by the end of Q3 was approx. NOK 30m. HBC will report 3rd
quarter 2017 financial results 15th November 2017.
For further information, please contact:
Roger Hofseth, CEO of Hofseth BioCare ASA
Mob: +47 95147941
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Mob: +47 93632966
About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers high-value ingredients and
finished products for humans and pets. The company is founded on the core values
of sustainability, traceability and optimal utilization of natural resources.
Through an innovative hydrolysis technology, HBC is able to preserve the quality
of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's
objective is to contribute to the efficient use of marine resources and deliver
quality products for ingredients and finished consumer products in the nutrition
Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in
Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list
with ticker "HBC". More information about Hofseth BioCare at
www.hofsethbiocare.com and www.facebook.com/hofsethbiocare
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.